Detalhe da pesquisa
1.
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
Ann Hematol
; 102(8): 2077-2085, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37012462
2.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Ann Hematol
; 102(10): 2741-2752, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37592092
3.
Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis.
Ann Allergy Asthma Immunol
; 128(3): 314-318, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34637924
4.
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Br J Haematol
; 194(2): 344-354, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34060083
5.
Proteins Marking the Sequence of Genotoxic Signaling from Irradiated Mesenchymal Stromal Cells to CD34+ Cells.
Int J Mol Sci
; 22(11)2021 May 29.
Artigo
Inglês
| MEDLINE | ID: mdl-34072546
6.
Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis.
Int J Mol Sci
; 22(5)2021 Mar 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33806359
7.
Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients.
Ann Hematol
; 99(5): 991-1006, 2020 May.
Artigo
Inglês
| MEDLINE | ID: mdl-32253454
8.
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Am J Hematol
; 95(7): 824-833, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32279331
9.
DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia.
Int J Mol Sci
; 21(4)2020 Feb 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32053969
10.
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.
Blood
; 130(2): 137-145, 2017 07 13.
Artigo
Inglês
| MEDLINE | ID: mdl-28424161
11.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Haematologica
; 104(5): 955-962, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30514803
12.
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
Genes Chromosomes Cancer
; 57(5): 252-259, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29341334
13.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Lancet Oncol
; 19(6): 747-757, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29735299
14.
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.
Blood
; 128(9): 1246-59, 2016 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27268087
15.
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.
J Med Genet
; 54(9): 640-650, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28600436
16.
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Blood
; 126(1): 42-9, 2015 Jul 02.
Artigo
Inglês
| MEDLINE | ID: mdl-25918346
17.
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Haematologica
; 102(6): 1035-1043, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28255023
18.
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Ann Hematol
; 96(9): 1463-1470, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28725989
19.
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Eur J Clin Invest
; 46(5): 392-7, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-26914980
20.
Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.
Ann Hematol
; 95(4): 557-62, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26797429